Journal of Clinical and Translational Endocrinology最新文献

{"title":"Corrigendum to “Safety and efficacy of semaglutide in post kidney transplants patients with type 2 diabetes or post-transplant diabetes” [J. Clin. Translat. Endoc. 36C (2024) 100343]","authors":"Moeber Mohammed Mahzari , Omar Buraykan Alluhayyan , Mahdi Hamad Almutairi , Mohammed Abdullah Bayounis , Yazeed Hasan Alrayani , Amir A. Omair , Awad Saad Alshahrani","doi":"10.1016/j.jcte.2024.100360","DOIUrl":"10.1016/j.jcte.2024.100360","url":null,"abstract":"","PeriodicalId":46328,"journal":{"name":"Journal of Clinical and Translational Endocrinology","volume":"38 ","pages":"Article 100360"},"PeriodicalIF":4.2,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141712363","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"PCSK7 levels in women with and without PCOS","authors":"Stephen L. Atkin , Alexandra E Butler , Tannaz Jamialahmadi , Amirhossein Sahebkar","doi":"10.1016/j.jcte.2024.100376","DOIUrl":"10.1016/j.jcte.2024.100376","url":null,"abstract":"","PeriodicalId":46328,"journal":{"name":"Journal of Clinical and Translational Endocrinology","volume":"38 ","pages":"Article 100376"},"PeriodicalIF":4.2,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142744321","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Eating habits and carotenoid skin content among children based on their attendance at the school meals: A cross-sectional pilot study","authors":"Giovanna Caparello ,&nbsp;Fabrizio Ceraudo ,&nbsp;Francesca Meringolo ,&nbsp;Giuseppina Augimeri ,&nbsp;Giuseppe Morino ,&nbsp;Daniela Bonofiglio","doi":"10.1016/j.jcte.2024.100378","DOIUrl":"10.1016/j.jcte.2024.100378","url":null,"abstract":"<div><h3>Objective</h3><div>The promotion of a healthy diet, such as the Mediterranean Diet (MD), among childhood is of a particular importance, since eating behaviors learned early in life have been shown to be maintained into adolescence and adulthood. The most efficient intervention in childhood is the active involvement of the schools.</div></div><div><h3>Design</h3><div>The aim of this study was to evaluate the adherence to the MD model and the skin carotenoid levels among children divided by their school lunch attendance.</div></div><div><h3>Methods</h3><div>This cross-sectional study involved 132 pupils (64 girls and 68 boys), divided between children who ate lunch at school (44%) and at home (56%). The children who had meals provided by the school participated in activities promoting the health benefits of fruits and vegetables. All participants underwent anthropometric measurements and assessment of the MD adherence and the physical activity using KIDMED and PAQ-C questionnaires, respectively, and skin carotenoid content using the Veggie Meter®.</div></div><div><h3>Results</h3><div>We found mean KIDMED and PAQ-C scores, while skin carotenoid content was below the normal range in our population sample. Interestingly, children who ate lunch provided by the school had significantly higher carotenoid scores with respect to those who had lunch at home (<em>p = 0.005</em>). In multiple regression analyses, we found that carotenoid scores were positively influenced by gender (<em>p = 0.03</em>), school lunch attendance (<em>p = 0.01</em>) and daily vegetable consumption (<em>p = 0.0002</em>) in our children population sample.</div></div><div><h3>Conclusions</h3><div>Our results suggest the importance of promoting a healthy lifestyle at the school to improve eating habits during childhood as a strategy for disease prevention across the lifespan.</div></div>","PeriodicalId":46328,"journal":{"name":"Journal of Clinical and Translational Endocrinology","volume":"38 ","pages":"Article 100378"},"PeriodicalIF":4.2,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142704911","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Glucagon-like peptide1 receptor agonist treatment of cystic fibrosis-related diabetes complicated by obesity: A cases series and literature review","authors":"Ammar Ahmed ,&nbsp;Anvitha Ankireddypalli ,&nbsp;Tasma Harindhanavudhi ,&nbsp;Antoinette Moran ,&nbsp;Amir Moheet","doi":"10.1016/j.jcte.2024.100375","DOIUrl":"10.1016/j.jcte.2024.100375","url":null,"abstract":"<div><div>Cystic fibrosis-related diabetes (CFRD) is the most common non-pulmonary comorbidity in people with cystic fibrosis (CF). Current guidelines recommend insulin therapy as the treatment of choice for people with CFRD. In the past, obesity and overweight were uncommon in individuals with CF. However, in recent years, advancements in CF therapies have led to a significant increase in the prevalence of overweight and obesity within this population. Glucagon-like peptide1 receptor agonist (GLP-1 RA) therapies could potentially improve glycemic control in people with CF by increasing insulin secretion, slowing gastric emptying, and promoting weight loss through central appetite suppression, which in turn can enhance insulin sensitivity. We report, for the first time, five cases of individuals with CFRD complicated by obesity treated with GLP 1-RA for at least two years. With GLP 1-RA therapy, 4 out of 5 individuals exhibited weight reduction ranging from 7% to 19% over two years, while forced expiratory volume in 1 s (FEV1)/predicted FEV1 % remained stable or improved in all cases. The impact on glycemic control was variable. Insulin requirements either reduced or remained stable in all five cases. Overall, GLP-1 RA was well tolerated in this case series; one individual discontinued the medication after two years of therapy due to poor appetite and nausea.</div></div>","PeriodicalId":46328,"journal":{"name":"Journal of Clinical and Translational Endocrinology","volume":"38 ","pages":"Article 100375"},"PeriodicalIF":4.2,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142655723","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The right drug for the right patient at the right time with the right test in differentiated thyroid cancer (DTC)","authors":"Dario de Biase ,&nbsp;Andrea Repaci ,&nbsp;Maria Concetta Nigro ,&nbsp;Thais Maloberti ,&nbsp;Francesca Carosi ,&nbsp;Maria A. Pantaleo ,&nbsp;Giovanni Tallini ,&nbsp;Margherita Nannini","doi":"10.1016/j.jcte.2024.100373","DOIUrl":"10.1016/j.jcte.2024.100373","url":null,"abstract":"<div><div>Thanks to the identification of crucial molecular pathways, the therapeutic landscape for advanced differentiated thyroid tumors (DTCs) has significantly improved during the last ten years. The therapeutic scenario has been greatly impacted by the discovery of mutually exclusive gene changes in the MAPK and PI3K/AKT pathways, such as <em>RET</em> or <em>NTRK</em> fusions and pathogenic mutations of the <em>BRAF</em> and <em>RAS</em> genes. Indeed, multi-kinase inhibitors and selective inhibitors have demonstrated outstanding efficacy for radioactive iodine-refractory (RAI-R) drug treatment, with overall response rates reaching up to 86%. Thus, for RAI-R DTCs, routine molecular testing for actionable gene alterations is now essential, for choosing the right therapy for the right patient.</div><div>Additionally, tumor genotyping also allows to identify a subset of patients with worse prognosis disease, which may deserve a tailored clinical management. Thus, the right test should also include non-driver <em>TERT</em>, <em>TP53</em>, <em>PIK3CA</em>, and other mutations of aggressiveness, with the aim of a molecular-based risk stratification. Therefore, tumor genotyping should be considered in the diagnostic work-up of metastatic DTC patients or with highly aggressive histological features, in order to give the right drug for the right patient at the right time.</div></div>","PeriodicalId":46328,"journal":{"name":"Journal of Clinical and Translational Endocrinology","volume":"38 ","pages":"Article 100373"},"PeriodicalIF":4.2,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143161734","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association between incretin-based drugs and risk of cholangiocarcinoma among patients with type 2 diabetes: A large population-based matched cohort study","authors":"Arunkumar Krishnan ,&nbsp;Carolin V. Schneider ,&nbsp;Hendrik-Tobias Arkenau ,&nbsp;Ezequiel Matias Mauro ,&nbsp;Alejandro Forner ,&nbsp;W. Scott Butsch ,&nbsp;Declan Walsh ,&nbsp;Saleh A. Alqahtani","doi":"10.1016/j.jcte.2024.100370","DOIUrl":"10.1016/j.jcte.2024.100370","url":null,"abstract":"<div><h3>Aim</h3><div>To examine the association between the use of incretin-based drugs [glucagon-like peptide-1 receptor agonists (GLP-1RAs), dipeptidyl peptidase-4 inhibitors (DPP-4Is)] and the risk of cholangiocarcinoma (CCA) in the United States.</div></div><div><h3>Methods</h3><div>This large population-based, retrospective cohort study using the TriNetX datasets included adult patients with type 2 diabetes mellitus (T2DM) who were new users of GLP-1RAs, DPP-4Is, or other second- or third-line antidiabetic drugs between 2010 and 2021. The primary outcome was the incidence of CCA.</div></div><div><h3>Results</h3><div>A total of 3,816,071 patients were included (mean age, 61.4 years, female, 49.3 %). A 51 % and 23 % risk reduction in CCA after 1 year of exposure to GLP-1RAs (hazard ratio 0.49; 95 % CI 0.40–0.60) and DPP4Is (0.77, 95 % CI 0.67–0.90), respectively compared to new second-or third-line users. Results were consistent at 3, 5, and 7 years of follow-up (0.66, 0.71, and 0.72 for GLP-1RAs and 0.84, 0.87, and 0.85 for DPP-4Is, respectively). Compared to new metformin users, GLP-1RA users were associated with a 42 % lower risk of developing CCA, whereas DPP-4I group was not associated with an increased risk.</div></div><div><h3>Conclusions</h3><div>GLP-1RAs and DPP-4Is were not associated with a significantly increased risk of CCA. GLP-1RAs even showed a reduced risk of CCA development. They can be considered as safe and effective treatment options for patients with T2DM at risk of CCA.</div></div>","PeriodicalId":46328,"journal":{"name":"Journal of Clinical and Translational Endocrinology","volume":"38 ","pages":"Article 100370"},"PeriodicalIF":4.2,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142320285","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Challenges of using telemedicine for patients with diabetes during the COVID-19 pandemic: A scoping review","authors":"Fatemeh Mirasghari ,&nbsp;Haleh Ayatollahi ,&nbsp;Farnia Velayati ,&nbsp;Arezoo Abasi","doi":"10.1016/j.jcte.2024.100361","DOIUrl":"10.1016/j.jcte.2024.100361","url":null,"abstract":"<div><h3>Background</h3><p>Telemedicine has aided patients with diabetes during the COVID-19 pandemic in receiving better healthcare services. However, despite its numerous benefits, the use of this technology has faced several challenges. This study aimed to identify the challenges of using telemedicine for patients with diabetes during the COVID-19 pandemic.</p></div><div><h3>Methods</h3><p>This scoping review was conducted in 2024. Relevant articles published between 2020 and 2023 were searched in databases including PubMed, Scopus, Web of Science, ProQuest, and the Cochrane Library. Initially, 822 articles were retrieved, and after screening 21 articles were selected.</p></div><div><h3>Results</h3><p>The challenges of using telemedicine for patients with diabetes during the COVID-19 pandemic were categorized into the clinical, individual, organizational, and technical challenges. The clinical challenges included the lack of physical examinations and unavailability of patients’ medical history. The individual challenges contained difficulties in using smart phones by patients and their low level of literacy. The organizational challenges were related to insufficient laws about obtaining patient consent and limited reimbursement for telemedicine services, and the technical challenges included limited access to the high-speed Internet services and inadequate technical infrastructure for telemedicine services. Most studies highlighted the role of individual and organizational challenges in using this technology.</p></div><div><h3>Conclusions</h3><p>Considering the numerous challenges experienced in using telemedicine for patients with diabetes during the COVID-19 pandemic, it seems that more attention should be paid to address each of these challenges to improve the actual usage, service quality, and user acceptance of telemedicine technology. This, in turn, can lead to saving costs and improving the health status and quality of life of patients with diabetes.</p></div>","PeriodicalId":46328,"journal":{"name":"Journal of Clinical and Translational Endocrinology","volume":"37 ","pages":"Article 100361"},"PeriodicalIF":4.2,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2214623724000322/pdfft?md5=590a27b9957d44dd1050d6802796d361&pid=1-s2.0-S2214623724000322-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141622727","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correlation study of multiple inflammatory indices and vertebral compression fracture: A cross-sectional study","authors":"Qi Fu,&nbsp;Cuiping Zhang,&nbsp;Yujiao Yang,&nbsp;Ruoling Teng,&nbsp;Fenfen Liu,&nbsp;Ping Liu,&nbsp;Long Wang,&nbsp;Jiao Wang,&nbsp;Yanan Chen,&nbsp;Yi Ding","doi":"10.1016/j.jcte.2024.100369","DOIUrl":"10.1016/j.jcte.2024.100369","url":null,"abstract":"<div><h3>Background</h3><p>Vertebral compression fractures (VCFs) are prevalent in patients with osteoporosis and pose significant health risks. Although chronic low-grade inflammation plays a crucial role in the pathogenesis of osteoporosis, the relationship between various inflammatory indices and the occurrence of fractures remains unclear.</p></div><div><h3>Objective</h3><p>This study aims to evaluate the correlation between multiple inflammatory indices, neutrophil-to-lymphocyte ratio (NLR), monocyte-to-lymphocyte ratio (MLR), platelet-to-lymphocyte ratio (PLR), systemic immune-inflammatory index (SII), and systemic inflammatory response index (SIRI), and VCFs, to explore the significance of these indices in clinical application.</p></div><div><h3>Methods</h3><p>Clinical data of 310 patients diagnosed with osteoporosis from November 2020 to June 2023 in the hospital were collected. The general conditions between fracture and non-fracture groups were described. Spearman analysis and binary logistic regression analysis were used to assess the relationship between inflammatory indices and VCFs. Receiver operating characteristic curve was used to evaluate the diagnostic efficacy of these inflammatory indices for VCFs.</p></div><div><h3>Results</h3><p>VCFs were diagnosed in 43.55 % of patients with osteoporosis. NLR(ρ = 0.169, P=0.003), MLR(ρ = 0.293, P&lt;0.001), SII(ρ = 0.126, P=0.027), and SIRI(ρ = 0.273, P&lt;0.001) were positively correlated with the occurrence of VCFs. NLR(OR=1.480, 95 %CI 1.114 ∼ 1.966, P=0.007), MLR(multiplied by 100, OR=1.048, 95 %CI 1.011 ∼ 1.087, P=0.011), and SIRI(OR=3.327, 95 %CI 1.510 ∼ 7.330, P=0.003) were independent risk factors for VCFs, hip bone mineral density (BMD) (OR=0.011, 95 %CI 0.001 ∼ 0.151, P=0.001) was an independent protective factor for VCFs. MLR(AUC 0.671, 95 % CI=0.610 ∼ 0.732, P &lt;0.001) had relatively high clinical diagnostic efficacy.</p></div><div><h3>Conclusion</h3><p>The neutrophil-to-lymphocyte ratio (NLR), monocyte-to-lymphocyte ratio (MLR), and systemic inflammatory response index (SIRI) are independent risk factors for vertebral compression fractures.</p></div>","PeriodicalId":46328,"journal":{"name":"Journal of Clinical and Translational Endocrinology","volume":"37 ","pages":"Article 100369"},"PeriodicalIF":4.2,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2214623724000401/pdfft?md5=086e3465529475372986cf9dfc5feee5&pid=1-s2.0-S2214623724000401-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142164396","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Letter to the Editor in response to the article “Semaglutide and post kidney transplantation in patients with diabetes”","authors":"Mai Hussein ,&nbsp;Youssef MK Farag","doi":"10.1016/j.jcte.2024.100358","DOIUrl":"https://doi.org/10.1016/j.jcte.2024.100358","url":null,"abstract":"","PeriodicalId":46328,"journal":{"name":"Journal of Clinical and Translational Endocrinology","volume":"37 ","pages":"Article 100358"},"PeriodicalIF":4.2,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2214623724000292/pdfft?md5=41a4bc5eb80e6f16728cb192ef776550&pid=1-s2.0-S2214623724000292-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141596588","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Testosterone deficiency and chronic kidney disease","authors":"Michael Zitzmann","doi":"10.1016/j.jcte.2024.100365","DOIUrl":"10.1016/j.jcte.2024.100365","url":null,"abstract":"&lt;div&gt;&lt;p&gt;Testosterone’s biological functions are extensive, influencing reproductive and systemic health. It plays a vital role in sexual functions, muscle protein synthesis, bone metabolism, fat distribution, and cardiovascular health. The hormone also affects mood, cognitive function, and erythropoiesis, underscoring its importance in both physical and mental health.&lt;/p&gt;&lt;p&gt;Testosterone deficiency, or male male hypogonadism, is increasingly recognized as a significant health issue affecting various bodily systems, also in the context of chronic kidney disease (CKD). Recent research indicates a complex interplay between testosterone levels and renal health, suggesting that male male hypogonadism may both impact and be impacted by CKD. The latter is characterized by a gradual loss of kidney function, affects millions globally and is often associated with diabetes mellitus, arterial hypertension, and autoimmune diseases. Men with CKD frequently experience lower testosterone levels, which can exacerbate muscle wasting, reduce quality of life, and increase cardiovascular risk. Overall, low testosterone levels in CKD patients are associated with increased morbidity and mortality.&lt;/p&gt;&lt;p&gt;Several mechanisms explain the relationship between CKD and testosterone deficiency. The uremic environment in CKD disrupts the hypothalamic-pituitary–gonadal axis, impairing hormone production. Nutritional deficiencies and chronic inflammation common in CKD patients further suppress gonadal function. The consequences of low testosterone in CKD are profound, with studies suggesting that testosterone replacement therapy (TRT) might improve clinical outcomes, though the long-term effects and causal relationships remain under investigation.&lt;/p&gt;&lt;p&gt;The potential benefits of TRT in CKD patients might be significant. TRT can enhance muscle mass and strength, address anemia by stimulating erythropoiesis, improve bone density, and possibly offer cardiovascular benefits by improving body composition and insulin sensitivity. General symptoms of male hypogonadism, such as deteriorated psychological, sexual and physical wellbeing, can be improved by TRT. However, these benefits must be weighed against potential risks. TRT may exacerbate fluid retention, arterial hypertension, or exacerbate existing heart failure, particularly in CKD patients with pre-existing cardiovascular comorbidities. Additionally, concerns about the progression of renal disease via several testosterone affected pathways involving renal tubular integrity exist, highlighting the need for careful patient selection and monitoring.&lt;/p&gt;&lt;p&gt;Understanding this relationship is crucial for developing comprehensive treatment strategies that address both renal and endocrine dysfunctions, highlighting the need for integrated patient care, which means good collaboration between subspecialists like nephrologists, endocrinologists, urologists and primary care providers, aiming to improve outcomes and quality of life while mitiga","PeriodicalId":46328,"journal":{"name":"Journal of Clinical and Translational Endocrinology","volume":"37 ","pages":"Article 100365"},"PeriodicalIF":4.2,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S221462372400036X/pdfft?md5=222c8ee0f1372b019af37078b82d8e74&pid=1-s2.0-S221462372400036X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141998341","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}